Blog

Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like chronic lymphocytic leukemia (CLL).What is the mechanism of action for Alemtuzumab?Alemtuzumab binds to CD52 on lymphocytes, leading to their depletion via immune-mediated cytotoxicity, resetting the immune system in diseases like MS.What are the clinical applications of Alemtuzumab?Alemtuzumab is FDA-approved for relapsing-remitting multiple sclerosis (RRMS) and is used off-label for various hematologic conditions.What are Alemtuzumab’s common side effects?Side effects include infusion-related …

Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the mechanism of action for Enavatuzumab?Enavatuzumab binds to Fn14, inhibiting signaling pathways that promote tumor cell proliferation and survival while enhancing immune response.What are the clinical applications of Enavatuzumab?It is under investigation for treating solid tumors and hematologic malignancies due to its dual action of direct tumor cell targeting and immune system modulation.Is Enavatuzumab safe?Emerging studies indicate a manageable safety profile, though further trials are crucial …

Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune destruction.What role does Praluzatamab play in targeting CD47?It blocks CD47–SIRPα signaling, promoting phagocytosis of tumor cells and enhancing antitumor immune responses.Is Praluzatamab safe?Initial studies reported tolerable safety profiles, but further trials were needed to fully assess its risks and hematologic side effects.What are the clinical applications of Praluzatamab?Praluzatamab has been investigated for treating myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and soli …

What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.What is the mechanism of action for Milatuzumab?Milatuzumab binds CD74, interrupting survival pathways and triggering antibody-dependent cell-mediated cytotoxicity (ADCC).Is Milatuzumab safe?Milatuzumab has shown manageable safety in early trials, though further studies are needed to fully define its toxicity profile.What diseases is Milatuzumab being studied for?Milatuzumab has been investigated in hematological malignancies like multiple myeloma and chronic lymphocytic leukemia, and autoimmune …

Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammatory autoimmune conditions.What is the mechanism of action for Guselkumab?It inhibits IL-23 signaling by binding to the p19 subunit, disrupting downstream inflammatory pathways involved in diseases like psoriasis and psoriatic arthritis.Is Guselkumab safe?Clinical trials have shown Guselkumab to have a favorable safety profile, with most side effects being mild to moderate, such as upper respiratory infections and injection-site reactions.What conditions does Guselkumab treat?Guselkumab is FDA-appr …

Quick Facts About NarsoplimabWhat is Narsoplimab?Narsoplimab is a human monoclonal antibody that targets MASP-2, a key enzyme in the lectin pathway of the complement system.What is the mechanism of action for Narsoplimab?Narsoplimab inhibits MASP-2, blocking the activation of the lectin complement pathway and reducing inflammatory damage in immune-mediated diseases.What are the clinical applications of Narsoplimab?It has been studied in IgA nephropathy, HSCT-TMA, and other inflammatory conditions, with emerging evidence in COVID-19-related trials.Is Narsoplimab FDA-approved?Narsoplimab has received Breakthrough Therapy designation, but full FDA approval is pending further data …

Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epithelial cancers.What is the mechanism of action for Farletuzumab?It binds to FRα on tumor cells and mediates cytotoxic effects via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and internalization.What are the clinical applications of Farletuzumab?It has been explored in clinical trials for epithelial ovarian cancer, particularly in combination with agents like carboplatin, paclitaxel, or eribulin.Is Farletuzumab used with Ecteribulin?Yes. Farletuzumab …

Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Does Icrucumab Work?By blocking VEGFR-1, Icrucumab prevents tumor blood vessel formation, limiting cancer growth and metastasis.What Are the Clinical Applications of Icrucumab?Icrucumab has been investigated for various cancers, including colorectal and lung cancers, though research is ongoing to determine its efficacy.1.) Understanding IcrucumabIcrucumab is a humanized monoclonal antibody developed to target vascular endothelial growth factor receptor 1 (VEGFR-1), a crucial mediator of tumor angio …

Quick Facts About PlonmarlimabWhat is Plonmarlimab?Plonmarlimab is a monoclonal antibody targeting GM-CSF, a cytokine involved in inflammation and immune responses.How does Plonmarlimab work?It inhibits GM-CSF, reducing inflammatory cytokine release and immune cell activation, making it a potential treatment for autoimmune conditions.What are the clinical applications of Plonmarlimab?It has been studied in conditions like rheumatoid arthritis and COVID-19-induced hyperinflammation.Is Plonmarlimab safe?Early trials suggest a favorable safety profile, but ongoing research continues to evaluate long-term effects.1.) Understanding PlonmarlimabPlonmarlimab is a humanized monoclonal …

Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By blocking CD47, Rosopatamab enhances macrophage-mediated phagocytosis of cancer cells.What is the mechanism of action for Rosopatamab?Rosopatamab binds to CD47, preventing its interaction with SIRPα on macrophages. This action disrupts the “don’t eat me” signal, allowing the immune system to recognize and destroy malignant cells.What are the clinical applications of Rosopatamab?Rosopatamab is being explored in clinical research for treating hematologic malignancies and solid tumors. Studies suggest i …

Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progression.What is the mechanism of action of Carlumab?Carlumab binds to CCL2, inhibiting its interaction with receptors and reducing inflammation-related signaling pathways that contribute to disease progression.What are the clinical applications of Carlumab?Carlumab has been explored for conditions such as cancer, fibrosis, and inflammatory diseases. Although clinical trials faced challenges, ongoing research continues to assess its therapeutic potential.1.) Understanding CarlumabCarlumab is a fully …

Quick Facts About Ladiratuzumab VedotinWhat is Ladiratuzumab Vedotin?Ladiratuzumab Vedotin is an antibody-drug conjugate (ADC) designed to target LIV-1, a protein commonly expressed in triple-negative breast cancer (TNBC).What is the mechanism of action of Ladiratuzumab Vedotin?It combines an anti-LIV-1 monoclonal antibody with monomethyl auristatin E (MMAE), a cytotoxic agent, delivering targeted therapy to cancer cells while minimizing damage to healthy tissues.What are the clinical applications of Ladiratuzumab Vedotin?Primarily investigated for TNBC, Ladiratuzumab Vedotin has been explored in clinical trials for its efficacy in patients with advanced or metastatic breast ca …

Quick Facts About TezepelumabWhat is Tezepelumab?Tezepelumab is a monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), a key driver of airway inflammation in severe asthma.How does Tezepelumab work?By blocking TSLP, Tezepelumab reduces inflammation across multiple pathways, making it effective for a broad range of asthma patients, regardless of biomarker levels.What are the clinical applications of Tezepelumab?Tezepelumab is FDA-approved for treating severe asthma and is being investigated for other inflammatory conditions, including atopic dermatitis and chronic rhinosinusitis with nasal polyps (CRSwNP).1.) Understanding TezepelumabTezepelumab represent …

Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Does Sirexatamab Work?It blocks CD47 from binding to SIRPα, preventing tumor cells from escaping macrophage-mediated phagocytosis.What Are the Clinical Applications of Sirexatamab?It has been studied for hematologic malignancies and solid tumors, offering potential for combination therapies in immuno-oncology.1.) Understanding SirexatamabSirexatamab is an advanced immunotherapy designed to target CD47, a crucial immune checkpoint often referred to as the "don’t eat me" signal. CD47 is overexpressed …

Quick Facts About BococizumabWhat is Bococizumab?Bococizumab is a monoclonal antibody that targets PCSK9, a protein involved in cholesterol regulation.How Does Bococizumab Work?It inhibits PCSK9, increasing LDL receptor availability and reducing LDL cholesterol levels.Was Bococizumab Approved for Use?Bococizumab was discontinued during Phase 3 trials due to immunogenicity concerns and lipid-lowering variability.What Are the Side Effects of Bococizumab?Clinical trials reported increased anti-drug antibodies, leading to reduced efficacy over time.1.) Understanding BococizumabBococizumab was developed as a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, a class of …

Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD47, Uliledlimab enhances the immune system's ability to recognize and destroy cancer cells.What is the mechanism of action for Uliledlimab?Uliledlimab binds to CD47 on tumor cells, preventing CD47 from interacting with its receptor, SIRPα, on immune cells. This blockage promotes phagocytosis of cancer cells by macrophages, aiding in the immune system's fight against tumors.What are the clinical applications of Uliledlimab?Uliledlimab is being investigated in clinical trials for its potential in …

Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for recurrent or metastatic cervical cancer.How does Tisotumab Vedotin work?It binds to TF-expressing cancer cells, delivering a cytotoxic payload that disrupts microtubules, leading to cancer cell death.What are the clinical applications of Tisotumab Vedotin?Primarily used for recurrent or metastatic cervical cancer, it is also being studied for use in other solid tumors.What are the key side effects of Tisotumab Vedotin?Common side effects include ocular toxicity, peripheral neuropathy, and fatig …

Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumors.How does Tidutamab work?Tidutamab binds to SSTR2, blocking signaling pathways that contribute to tumor growth and survival, thereby enhancing anti-tumor immune responses.What are the clinical applications of Tidutamab?Tidutamab is being explored for treating neuroendocrine tumors, particularly those expressing high levels of SSTR2, with ongoing research investigating its potential in combination therapies.1.) Understanding TidutamabTidutamab is a promising therapeutic agent being explored for …

Quick Facts About EnokizumabWhat is Enokizumab?Enokizumab is a monoclonal antibody designed to target interleukin-9 (IL-9), a cytokine involved in inflammatory responses. It has been studied primarily for its potential in treating immune-mediated conditions.How Does Enokizumab Work?Enokizumab inhibits IL-9 signaling, reducing inflammation and immune system overactivity. This makes it a candidate for treating conditions like asthma and other allergic diseases.What Are the Clinical Applications of Enokizumab?Enokizumab has been explored for treating conditions such as asthma, atopic dermatitis, and other inflammatory disorders. Research is ongoing to evaluate its full therapeutic …

Quick Facts About NarnatumabWhat is Narnatumab?Narnatumab is a monoclonal antibody targeting CD47, a key immune checkpoint that helps cancer cells evade destruction by the immune system.What is the mechanism of action for Narnatumab?Narnatumab blocks CD47, a "don't eat me" signal used by cancer cells to avoid phagocytosis. This enhances macrophage-mediated immune responses against tumors.What are the clinical applications of Narnatumab?Narnatumab is being investigated for its potential in treating hematologic malignancies and solid tumors, with ongoing research exploring its efficacy in combination therapies.1.) Understanding NarnatumabNarnatumab is a promising therapeutic agen …

Quick Facts About AnifrolumabWhat is Anifrolumab?Anifrolumab is a monoclonal antibody that targets the type I interferon receptor, playing a crucial role in treating systemic lupus erythematosus (SLE).What is the mechanism of action for Anifrolumab?Anifrolumab blocks type I interferon signaling, reducing inflammation and immune overactivation associated with lupus.What are the clinical applications of Anifrolumab?It is primarily approved for treating moderate to severe systemic lupus erythematosus (SLE) in adults who do not respond to standard therapy.1.) Understanding AnifrolumabAnifrolumab is a promising breakthrough in the field of immunotherapy, particularly for the treatme …

Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the mechanism of action for Lacnotuzumab?By blocking CD47, Lacnotuzumab enhances macrophage-mediated phagocytosis, allowing the immune system to recognize and eliminate cancer cells.What are the clinical applications of Lacnotuzumab?Lacnotuzumab has been studied in clinical trials for its potential in treating solid tumors and hematologic malignancies, often in combination with other immunotherapies.1.) Understanding LacnotuzumabLacnotuzumab is an emerging therapeutic agent within the field of immuno-o …

Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tumors and hematologic malignancies.What is the mechanism of action of Lorvotuzumab?Lorvotuzumab binds to CD56-positive cancer cells, delivering a cytotoxic payload (mertansine) to induce apoptosis and inhibit tumor growth.What are the clinical applications of Lorvotuzumab?Research on Lorvotuzumab has focused on treating small cell lung cancer (SCLC), multiple myeloma, and acute myeloid leukemia (AML). While some trials were discontinued, interest in its mechanism persists in oncology.1.) Understa …

Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cell trafficking.What is the mechanism of action for Ulocuplumab?Ulocuplumab blocks CXCR4, disrupting cancer cell survival signals, mobilizing hematopoietic stem cells, and enhancing immune response against tumors.What are the clinical applications of Tinurilimab?Research has explored Ulocuplumab’s potential in treating acute myeloid leukemia (AML), multiple myeloma, and solid tumors like pancreatic cancer.Why was Ulocuplumab discontinued?Bristol-Myers Squibb discontinued Ulocuplumab’s development, …